– USA, WI – Exact Sciences Corp. (NASDAQ: EXAS) today announced the appointment of Michael S. Wygza to its board of directors. Wygza most recently served as President, Chief Executive Officer and a member of the board of directors of Radius Health, Inc.
“Michael’s impressive corporate leadership track record, deep life sciences industry expertise and extensive finance background make him a valuable addition to our board,” said Kevin Conroy, CEO and chairman of Exact Sciences. “Michael understands the complexities of bringing new tests to patients. He will be a critical asset to Exact Sciences as we advance our pipeline of new cancer screening technologies and expand patient and provider access to Cologuard®, the first FDA-approved noninvasive stool DNA screening test for colorectal cancer.”
At Exact Sciences, Wygza will serve as a member of the Board’s Audit Committee where he brings more than two decades of experience leading corporate finance divisions with some of the nation’s foremost biopharmaceutical companies. From 2011 to 2013, he served as President, CEO and board member of Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health conditions. Prior to Radius, he held multiple senior management roles at Genzyme Corporation, including Chief Financial Officer from 1999 to 2011 and Executive Vice President of Finance from 2003 to 2011. He currently serves as a director for pharmaceutical companies Akebia Therapeutics, Inc. and Oncomed Pharmaceuticals, Inc. Wygza received his B.S. from Suffolk University and his M.B.A. from Providence College.
About Exact Sciences Corp.
Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Cologuard is included in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is included in the U.S. Multi-Society Task Force on Colorectal Cancer.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
